Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117767 · ClinicalTrials.gov registry record · Phase 3
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
NCT00117767 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 720 participants.
The verdict
NCT00117767, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
Study Summary
Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
Interventions
- DRUG Terbinafine hydrochloride (HCl)
- DRUG Griseofulvin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2004-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117767
The ClinicalTrials.gov registry entry for NCT00117767 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Terbinafine hydrochloride (HCl) is the first listed.
NCT00117767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00117767 about?
NCT00117767 is a clinical study titled "Terbinafine Compared to Griseofulvin in Children With Tinea Capitis". Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by ...
What is the current status of trial NCT00117767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2004-06.
What interventions are being tested in trial NCT00117767?
The interventions under investigation include: Terbinafine hydrochloride (HCl) (DRUG), Griseofulvin (DRUG).
Who is sponsoring clinical trial NCT00117767?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.